• Deborah Barthel, Gerd Ganser, Rolf-Michael Kuester, Nils Onken, Kirsten Minden, Hermann Josef Girschick, Anton Hospach, and Gerd Horneff.
• From the Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin; Department of Pediatric Rheumatology, St. Josef-Stift Sendenhorst, Sendenhorst; Asklepios Rheumazentrum Hamburg, Hamburg; Pediatric Practice, Lueneburg; Deutsches Rheuma-Forschungszentrum, Berlin; Department of Pediatrics, Vivantes Klinikum im Friedrichshain, Berlin; Department of Pediatrics, Klinikum Stuttgart, Stuttgart, Germany.D. Barthel, MD, Department of Pediatrics, Asklepios Klinik Sankt Augustin; G. Ganser, MD, Department of Pediatric Rheumatology, St. Josef-Stift Sendenhorst; R.M. Kuester, MD, Senior Consultant, Asklepios Rheumazentrum Hamburg; N. Onken, MD, Pediatric Practice; K. Minden, MD, Deutsches Rheuma-Forschungszentrum; H.J. Girschick, MD, Department of Pediatrics, Vivantes Klinikum im Friedrichshain; A. Hospach, MD, Department of Pediatrics, Klinikum Stuttgart; G. Horneff, MD, Department of Pediatrics, Asklepios Klinik Sankt Augustin. d.barthel@asklepios.com.
• J Rheumatol. 2015 Nov 1; 42 (11): 2160-5.

ObjectiveEvolving inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) and might be associated with JIA therapy.MethodsData from the German biologics registry (Biologika in der Kinderrheumatologie; BiKeR) from 2001 to 2013 were analyzed.ResultsThere were 3071 patients with 8389 patient-years (PY) of observation followed. IBD was diagnosed in 11 patients, 8 with Crohn disease and 3 with ulcerative colitis. IBD incidence in patients with JIA was 1.31/1000 PY and higher than published IBD incidences in pediatric populations. Compared with the total BiKeR cohort, patients with IBD more commonly had enthesitis-related arthritis, extended oligoarthritis, psoriatic arthritis, and also rheumatoid factor (RF)-negative polyarthritis. No IBD occurred in patients with systemic JIA or RF-positive polyarthritis. In patients treated with methotrexate (MTX), the IBD incidence was significantly lower compared with patients not treated with MTX. Etanercept (ETN) monotherapy, but not the combination of ETN and MTX, was associated with an increased incidence of IBD.ConclusionIncidence of IBD in patients with JIA is higher than in the population. MTX turned out to be protective, even in combination with ETN.

38 keywords...

hide…